Over the weekend, the scientific and investing communities had a first look at 1-year follow-up results for AMT-110, uniQure’s (QURE) gene therapy candidate for the treatment of Sanfilippo B. Details are limited as uniQure negotiates the acquisition of this data from partner Institut Pasteur, but so far we’re encouraged by the results. A conference call Monday morning helped fill in some gaps, and our view is that uniQure has an intriguing drug candidate on its hands, certainly worth moving forward into larger studies.
Already a Premium user? Sign In
